Health-care companies rallied after strong earnings.
Johnson & Johnson's sales climbed a stark 11% in the third quarter, reflecting as more doctor's visits and medical procedures drove sales of medical devices and pharmaceuticals that had slowed when the pandemic disrupted the health-care industry.
An oral Covid-19 treatment developed by Atea Pharmaceuticals failed to prove efficacy in a midstage trial, triggering a plunge in the company's shares.
Shares of Swiss drug giant Roche Holding, which co-developed the Covid pill, fell after results showed the treatment didn't cut viral load in nonhospitalized patients with mild to moderate symptoms.
Write to Rob Curran at firstname.lastname@example.org
(END) Dow Jones Newswires